Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study.

Curman P, Thapa M, Ludwig RJ, Kasperkiewicz M

Open source

DOI
10.1111/jdv.70759
Published
2026 Sep 19
Container
Journal of the European Academy of Dermatology and Venereology : JEADV
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/jdv.70759,
  title = {Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study.},
  author = {Curman P and Thapa M and Ludwig RJ and Kasperkiewicz M},
  year = {2026},
  journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
  doi = {10.1111/jdv.70759},
  url = {https://doi.org/10.1111/jdv.70759}
}

RIS

TY  - JOUR
TI  - Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study.
AU  - Curman P
AU  - Thapa M
AU  - Ludwig RJ
AU  - Kasperkiewicz M
PY  - 2026
JO  - Journal of the European Academy of Dermatology and Venereology : JEADV
DO  - 10.1111/jdv.70759
UR  - https://doi.org/10.1111/jdv.70759
ER  - 

APA

P, C., M, T., RJ, L., & M, K. (2026). Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70759

Source records